Anti-CD20 Monoclonal Antibodies Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Anti-CD20 Monoclonal Antibodies Market Forecast: What Market Value Is Expected By 2030?
The market for anti-CD20 monoclonal antibodies has experienced robust expansion over recent years. Projections indicate it will rise from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historic growth has been driven by several factors, including the approval and extensive adoption of rituximab, an increasing prevalence of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, heightened recognition of targeted therapeutic approaches, the accessibility of hospital pharmacy distribution networks, and a broadening range of intravenous administration pathways.
The market for anti-cd20 monoclonal antibodies is anticipated to demonstrate significant growth over the next several years, reaching $12.94 billion by 2030 at a compound annual growth rate of 7.5%. This forecasted expansion is driven by the emergence of obinutuzumab and ofatumumab biosimilars, broader adoption of subcutaneous formulations, increased research and academic funding, the growth of ambulatory care centers, and rising demand for anti-cd20 therapies across multiple autoimmune conditions. During the forecast period, major trends will include greater use of monoclonal antibody treatments for B-cell malignancies, the creation of biosimilars and next-generation anti-cd20 antibodies, expanded subcutaneous and patient-friendly administration methods, a heightened emphasis on personalized and targeted immunotherapy, and an upsurge in clinical trials and research activities in both autoimmune and oncology indications.
Download A Free Sample Report For Comprehensive Market Insights:
Anti-CD20 Monoclonal Antibodies Market Expansion Supported By Key Demand Factors
The anticipated increase in autoimmune conditions is set to drive forward the anti-CD20 monoclonal antibodies market. These disorders arise when the immune system mistakenly targets the body’s own cells as foreign and mounts an assault against them. Their prevalence is climbing due to heightened exposure to environmental contaminants, which can disrupt immune regulation and provoke attacks on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune diseases by removing B cells responsible for generating autoantibodies and triggering inflammation. This therapy aids in modulating immune responses and alleviating disease manifestations. As an example, in February 2024, Arthritis Australia, a non-profit entity based in Australia, reported that an estimated 562,378 Australians will be affected by rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases that year. By 2040, this figure is projected to surge by 33% to 748,721 individuals, marking an increase of 186,343 Australians living with RA relative to 2025. Consequently, the rising incidence of autoimmune diseases is fueling expansion in the anti-CD20 monoclonal antibodies market.
Anti-CD20 Monoclonal Antibodies Market Segment Landscape: Which Areas Lead Market Development?
The anti-cd20 monoclonal antibodies market covered in this report is segmented –
1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications
5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users
Subsegments:
1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux
2) By Obinutuzumab: Gazyva, Biosimilar Candidates
3) By Ofatumumab: Arzerra, Kesimpta
4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab
Anti-CD20 Monoclonal Antibodies Market Growth Trends Influencing Competitive Dynamics
Key players within the anti-CD20 monoclonal antibody sector are concentrating on creating next-generation therapies like obinutuzumab to better address resistant or recurrent B-cell malignancies. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is engineered to identify and eliminate CD20-positive B cells that are involved in specific blood cancers and autoimmune conditions. As an illustration, in March 2025, Roche—a biopharmaceutical firm headquartered in Switzerland—revealed that the US Food and Drug Administration (FDA) had accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) aimed at treating lupus nephritis. This decision is based on favorable findings from the Phase III REGENCY study, where obinutuzumab combined with conventional therapy resulted in a higher complete renal response (CRR) compared to conventional therapy alone. This development positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show this kind of advantage in lupus nephritis, a serious kidney inflammation brought on by lupus that may progress to kidney failure.
Anti-CD20 Monoclonal Antibodies Market Industry Leaders And Market Competition
Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.
Access The Complete Anti-CD20 Monoclonal Antibodies Market Report:
Anti-CD20 Monoclonal Antibodies Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
